D A Van Echo
Overview
Explore the profile of D A Van Echo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richard 3rd H, Coldwell D, Murthy R, Van Echo D
J Vasc Interv Radiol
. 2001 Apr;
12(3):373-5.
PMID: 11287517
The authors report their experience with the Pleurx tunneled catheter in patients with end-stage abdominal carcinomatosis and intractable ascites. Ten patients with intractable ascites and abdominal carcinomatosis underwent placement of...
2.
Suntharalingam M, Haas M, Van Echo D, Haddad R, Jacobs M, Levy S, et al.
Cancer
. 2001 Feb;
91(3):548-54.
PMID: 11169937
Background: The objective of this study was to determine prognostic factors for response and survival on three consecutive institutional trials utilizing concurrent chemotherapy and radiation for locally advanced squamous cell...
3.
Tkaczuk K, Zamboni W, Tait N, Meisenberg B, Doyle L, Edelman M, et al.
Cancer Chemother Pharmacol
. 2001 Jan;
46(6):442-8.
PMID: 11138457
Purpose: Both docetaxel (DOC), a promoter and stabilizer of microtubule assembly, and topotecan (TOPO), a topoisomerase I inhibitor, have shown antitumor activity in a variety of solid tumor malignancies. This...
4.
Zamboni W, Egorin M, Van Echo D, Day R, Meisenberg B, Brooks S, et al.
J Clin Oncol
. 2000 Sep;
18(18):3288-94.
PMID: 10986062
Purpose: The sequence in which chemotherapeutic agents are administered can alter their pharmacokinetics, therapeutic effect, and toxicity. We evaluated the pharmacokinetics and pharmacodynamics of docetaxel and topotecan when coadministered on...
5.
Suntharalingam M, Haas M, Conley B, Egorin M, Levy S, Sivasailam S, et al.
Int J Radiat Oncol Biol Phys
. 2000 Apr;
47(1):49-56.
PMID: 10758304
Purpose: Unresectable squamous cell carcinomas of the head and neck (SCCHN) continue to pose a significant therapeutic challenge. This report defines the toxicities, efficacy, and prognostic factors associated with the...
6.
Park S, GRAY W, Hernandez I, Jacobs M, Ord R, Sutharalingam M, et al.
Clin Cancer Res
. 2000 Mar;
6(3):847-54.
PMID: 10741706
Although retinoids show promise for prevention of second primary upper aerodigestive tract tumors, the optimum retinoid, dose, and schedule are unknown. All-trans retinoic acid (ATRA) has greater affinity for retinoic...
7.
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
Conley B, Egorin M, Tait N, Rosen D, Sausville E, Dover G, et al.
Clin Cancer Res
. 1998 May;
4(3):629-34.
PMID: 9533530
Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions,...
8.
Conley B, Egorin M, Sridhara R, Finley R, Hemady R, Wu S, et al.
Cancer Chemother Pharmacol
. 1997 Jan;
39(4):291-9.
PMID: 9025769
A phase I trial of all-trans-retinoic acid (ATRA) was conducted to establish the maximum tolerable dose (MTD) of ATRA given once daily to patients with solid tumors. Cancer patients for...
9.
Mitchell E, Perry M, Luikart S, Cirrincione C, Van Echo D, Herndon 2nd J, et al.
Lung Cancer
. 1996 Sep;
15(2):215-23.
PMID: 8882988
Patients with untreated extensive small cell lung cancer (SCLC) with CALGB performance scores 0-2 were treated with etoposide 200 mg/m2/day on days 1-3 and cisplatin doses of 20, 30, or...
10.
Ratain M, Rosner G, Allen S, Costanza M, Van Echo D, Henderson I, et al.
J Clin Oncol
. 1995 Mar;
13(3):741-7.
PMID: 7884434
Purpose: To determine if variability in toxicity of amonafide during phase II trials could be correlated with pharmacokinetic variability. Patients And Methods: Seventy-three patients enrolled onto three Cancer and Leukemia...